COMMUNIQUÉS West-GlobeNewswire

HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq
23/01/2024
HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq 1er tour institutionnel pour HEPHAISTOS, en bonne voie pour amener son produit phare ONCO- [...]
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN
23/01/2024
Avextra, the German pharmaceutical company focused on Cannabis-Based Medicines (CBM) and the German Pain Association (DGS), the leading physicians’ society dedicated to chronic pain therapy, jointly announces their [...]
Ex dividend NOK 0.75 today
23/01/2024
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.
Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion
23/01/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 23 JANUARY 2024 at 9.00 EET Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion [...]
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
23/01/2024
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech The rapidly growing $130 billion coffee industry is at risk as [...]
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
23/01/2024
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy and complements 30-year heritage [...]
Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique
23/01/2024
Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique Cette [...]
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
23/01/2024
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 23 January 2024, 07:00 am CET DSMB i rates DSR 2.0 as safe following review of data from non-randomized cohort Data from non-randomized cohort confirms dramatic [...]
iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone® 70
23/01/2024
Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational Louvain-la-Neuve, Belgium, January 23, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in [...]
iThemba LABS prêt à produire du strontium-82 et du germanium-68 avec un Cyclone® 70 d'IBA
23/01/2024
Cyclotron de 70 MeV désormais pleinement opérationnel suite à la finalisation des tests d’acceptation. Louvain-la-Neuve, Belgique, le 23 janvier 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des [...]
BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis
23/01/2024
PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the [...]
BioSenic dépose une demande de protection supplémentaire par brevet, suite à de nouvelles preuves cliniques de l'efficacité de JTA-004 dans le traitement de l'arthrose
23/01/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE À la suite d'une analyse post hoc d'un essai de phase 3 démontrant un soulagement de la douleur chez les patients souffrant d'arthrose sévère du genou, Biosenic a déposé [...]
Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™
23/01/2024
Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20 th annual WORLD Symposium ™ Four posters with baseline data from the natural history (PRONTO) study in patients with GM1 [...]
The International Myeloma Foundation Mourns the Passing of IMF Board Member Dr. Edith Mitchell
23/01/2024
STUDIO CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members, Clinical Professor of Medicine and [...]
ARCPOINT ANNOUNCES CLOSING OF US$1.1 MILLION NON-BROKERED PRIVATE PLACEMENT
23/01/2024
Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) is pleased to [...]
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
23/01/2024
Company Announcement COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech, Inc [...]
Terranueva annonce le résultat favorable de l’assemblée des créanciers tenue suite au dépôt d’un avis d’intention
23/01/2024
MONTRÉAL, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Terranueva Corporation (CSE: TEQ) (« Terranueva » ou la « Société ») est heureuse d’annoncer que l’assemblée des créanciers tenue aujourd’hui a accepté à 86% la proposition de [...]
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
22/01/2024
Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx ® and atezolizumab in metastatic castration-resistant [...]
Ipsen présente les dernières données d'un essai de Phase III évaluant Cabometyx® en association avec une immunothérapie à l'occasion de l'édition 2024 de l'ASCO sur les cancers génito-urinaires
22/01/2024
Les premiers résultats détaillés de l'essai de Phase III CONTACT-02 ont démontré un bénéfice statistiquement significatif en matière de survie sans progression pour Cabometyx ® en association avec l'atézolizumab dans le [...]

Pages